Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes the company as currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event at the end. Let's analyze the transcript. Key points: - Q1 2024 revenue was disappointing, below expectations. - They mention challenges: slower conversion of new accounts for full-thickness skin defects, and burns business below expectations due to data issues. - They talk about RECELL GO nearing end of 180-day FDA review, ending May 30, 2024. They have inventory ready, and top 28 burn accounts prioritized for conversion in June. - They also mention PermeaDerm launch in March, but revenue less than 1%. - They talk about expanding portfolio, exploring wound bed preparation and dermal replacement products. - They mention international expansion, CE mark for RECELL GO expected between September and December. - They mention vitiligo initiative, TONE study, PMA supplement for RECELL GO mini in June, etc. Now, the question: Does management describe the company as CURRENTLY LIVING THROUGH A DEFINED WAITING PERIOD IT IS PAYING FOR OUT OF ITS OWN POCKET? That is, is there a real ongoing cost for something whose benefit has not arrived yet, and the end is a specific near-dated event? Look for evidence: - They have hired sales team, expanded commercial organization in Q2 2023. That is ongoing cost. - They have inventory for RECELL GO, ready for launch. They are waiting for FDA approval. That is a waiting period. - They have costs for clinical trials, etc. But is the company "paying now for something not yet earning"? Yes, they have invested in sales force, inventory, etc. But is that described as a defined waiting period? They are waiting for FDA approval of RECELL GO, which is a specific event. They have inventory ready. They are also waiting for CE mark, etc. However, the question asks: "Does management describe the company as CURRENTLY LIVING THROUGH A DEFINED WAITING PERIOD IT IS PAYING FOR OUT OF ITS OWN POCKET?" The key is that the cost is real and currently landing, and the wait is the main current work, and the far side is a specific near-dated event. In the transcript, management talks about the disappointing quarter, but they attribute it to slower conversion of new accounts and burns business below expectations.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.